Ovarian Cancer
Return to Library
|
Free Ovarian Cancer Articles |
|
|
|
|
New ovarian cancer data have been reported by T. Goto and co-authors
2009 AUG 24 - (NewsRx.com) -- According to recent research published in the International Journal of Cancer, "The aim of this study is to investigate p16INK4a expression by immunocytochemistry for ascites in advanced ovarian cancer and explore the possibility to predict chemotherapeutic response and prognosis. The immunocytochemical study was performed on cytology of ascites obtained from 37 Stage III or Stage IV ovarian cancer patients with measurable disease before platinum/taxane-based first-line chemotherapy following primary cytoreductive surgery or as neoadjuvant chemotherapy." "Twenty-one of 21 (100%) responders and 6 of 16 (44%) nonresponders showed p16INK4a immunopositivity (p < 0.001). Immunopositivity was frequently observed in serous adenocarciomas (17 of 18, 94%). Overall survival was significantly better in immunopositive cases compared with immunonegative cases (p = 0.0006). For subcellular localization, cytoplasm was diffusely positive in immunopositive cases (n = 27), 12 of which showed stronger nuclear immunostaining and demonstrated superior overall survival. fit vitro expression of p16INK4a protein was also examined for both parent chemosensitive and acquired chemoresistant ovarian cancer cell lines. Chemosensitive KF28 parent cells showed stronger nuclear staining compared with chemoresistant KFr13Tx cells showing stronger cytoplasmic staining by immunocytochemistry, which were also confirmed by western blotting," wrote T. Goto and colleagues. The researchers concluded: "Our data suggest that p16INK4a expression in cytology of ascites is a candidate marker in prediction of the primary response to chemotherapy." Goto and colleagues published their study in International Journal of Cancer (p16INK4a expression in cytology of ascites and response to chemotherapy in advanced ovarian cancer. International Journal of Cancer, 2009;125(2):339-344). For additional information, contact T. Goto, Saitama Med University, International Med Center, Center Comprehensive Cancer, Dept. of Gynecology Oncology, 1397-1 Yamane, Hidaka, Saitama 3501298, Japan. The publisher's contact information for the International Journal of Cancer is: Wiley-Liss, Division John Wiley & Sons Inc., 111 River St., Hoboken, NJ 07030, USA. Keywords: Japan, Hidaka, Ascites, Chemotherapy, Cytology, Drug Therapy, Gynecology, Oncology, Ovarian Cancer, Ovarian Carcinoma, Surgery, Women's Health. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
